Customized Immunotherapy Research Models

About Immunotherapy

Immunotherapy is an innovative area of research that targets and utilizes the body’s immune system to fight cancer cells. These therapies include therapeutic antibodies (e.g mABs, antibody-drug conjugates, & bispecific antibodies), checkpoint inhibitors (e.g. PD-1/PD-L1 inhibitors), adoptive cell therapies (e.g. CAR-T), and TCR therapies. The need to develop agents that are effective in patients with various types of cancer is one of many challenges scientists face today. Our team utilizes breaking edge tools and technologies to provide customized genetically engineered cells for novel cellular therapy and immunotherapy.

Customized tumor-associated antigen panels for Immuno-oncology discovery and potency assays:

  • Pre-validated ZFNs/CRISPR for knockout generation
  • Pre-designed Lentiviral vectors (+/- fluorescent protein/luciferase) and high titer Lentiviral particles for antigen expression cell lines
  • 3-4 cell lines in 4 months for your Immunotherapy research needs

Our assays are designed to ensure consistency, tailored for each project, and to meet your requirements and goal. Custom assay creation includes:

  • Tell us what antigen you'd like to use or pick your antigen target of interest:
  • Supply your own cells or select from our biologically-relevant cell models:
A375 A549 HCT116 MCF7 Raji RPMI-8226 U-266
  • Your preferred reporter readout (if needed)- fluorescent protein or luciferase.

Our offerings include (but are not limited to):

  • Cell-based assay development to evaluate the efficacy, potency, & mechanism of action of candidate therapies
  • Expression of patient-specific or modified T cell receptors (TCRs) or CARs of interest using a modular “landing pad” cassette
  • Tumor-associated antigen knockout or overexpression cell lines
  • Checkpoint inhibitor knockout or overexpression cell lines
  • Development of CAR-expression viral production cell lines
  • Genome editing in primary immune cell lines
  • Engineered cell lines to evaluate cell or gene therapy(s) of interest (research use only) prior to GMP expansion and banking